IP Library Granted Patent US 9,988,633
Granted Patent B2
US 9,988,633 · App. 15/678,362 · Granted Jun 5, 2018

Compositions and methods to promote erythropoiesis

Inventors: Emery H. Bresnick (Middleton, WI); Yoon A. Kang (San Francisco, CA); Skye McIver (Madison, WI)
Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
C12N15/113C12N15/1137C12Y301/13C12N2310/11C12N2310/12C12N2310/14C12N2310/15C12N2310/531C12N2320/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,988,633
App. No.
15/678,362
Granted
Jun 5, 2018
Kind
B2
Abstract

Described herein are compositions and methods for enhancing erythropoiesis in an individual in need thereof. Specifically agents that decrease the expression of Exosc10, such as inhibitory nucleic acid molecules, produce an increase in red blood cell production in the individual.

Claims (9)

1. A method of enhancing erythropoiesis in an individual in need thereof, comprising administering an effective amount of an agent that decreases the expression of Exosc10, wherein the agent produces an increase in red blood cell production in the individual, and wherein the agent is an inhibitory nucleic acid molecule that selectively decreases the expression of Exosc10.

2. The method of claim 1 , wherein the individual is a human in need of treatment for an anemic disorder, hemophilia, thalassemia, sickle cell disease, bone marrow transplantation, hematopoietic stem cell transplantation, thrombocytopenia, pancytopenia, or hypoxia.

3. The method of claim 2 , wherein the anemic disorder is associated with aging, infectious disease, chronic renal failure, end-stage renal disease, renal transplantation, cancer, AIDS, antiviral therapy, chronic stress, chemotherapy, radiation therapy, bone marrow transplantation, nutritional iron deficiency, blood-loss, hemolysis, or is of genetic origin.

4. The method of claim 3 , wherein the individual has a reduced hematocrit.

5. The method of claim 1 , wherein the inhibitory nucleic acid molecule is a small interfering RNA, an antisense RNA, a ribozyme, or a triple helix nucleic acid.

6. The method of claim 5 , wherein the small interfering RNA is an siRNA or an shRNA.

7. The method of claim 6 , wherein the small interfering RNA comprises 19 to 29 nucleotides that are substantially complementary to a sequence of 19 to 29 nucleotides of Exosc10.

8. The method of claim 7 , wherein Exosc10 has SEQ ID No. 8 or 15.

9. The method of claim 7 , wherein the small interfering RNA is an siRNA having SEQ ID NO. 29, 30, 31 or 32, the corresponding sequence of SEQ ID NO. 8, or a combination.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 18, 2017
From: UNIVERSITY OF WISCONSIN-MADISON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 043603/0892 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2017
From: BRESNICK, EMERY; KANG, YOON; MCIVER, SKYE
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 043319/0586 →
Continuity (4)
Division 15335529 · Oct 27, 2016
Division 14323175 · Jul 3, 2014
Provisional Application 61842569 · Jul 3, 2013
Related Publication 20180010129A1 · Jan 11, 2018